Sirtex falls on Phase III SIR-Sphere results

Sirtex Medical Ltd. (ASX:SRX) plummeted A$21.47 (55%) to A$17.53 on Tuesday after SIR-Spheres missed the primary endpoint of significantly improving progression-free survival (PFS) when added to first-line chemotherapy in the Phase III SIRFLOX trial to treat non-resectable metastatic colorectal cancer (mCRC).

SIR-Spheres led to a statistically significant improvement in PFS in the liver, a secondary endpoint. SIR-Spheres consists of yttrium-90 microspheres used for Selective Internal Radiation Therapy (SIRT). The product is approved in several countries to treat unresectable liver tumors. ...